- 专利标题: Fusion proteins with specificity for ED-B and long serum half-life for diagnosis or treatment of cancer
-
申请号: US16761677申请日: 2018-11-05
-
公开(公告)号: US11414466B2公开(公告)日: 2022-08-16
- 发明人: Erik Fiedler , Ulrich Haupts , Anja Katzschmann , Eva Bosse-Doenecke , Manja Gloser
- 申请人: Navigo Proteins GmbH
- 申请人地址: DE Halle/Saale
- 专利权人: Navigo Proteins GmbH
- 当前专利权人: Navigo Proteins GmbH
- 当前专利权人地址: DE Halle/Saale
- 代理机构: Jenkins, Wilson, Taylor & Hunt, P.A.
- 优先权: EP17200425 20171107
- 国际申请: PCT/EP2018/080174 WO 20181105
- 国际公布: WO2019/091918 WO 20190516
- 主分类号: C07K14/47
- IPC分类号: C07K14/47
摘要:
The invention relates to fusion proteins comprising at least one extradomain B of fibronectin (ED-B) specific binding domain with high stability in serum and at least one APS domain essentially consisting of or consisting of up to about 80 amino acids selected from alanine, proline, serine, and optionally aspartic acid. The fusion protein further comprises at least one coupling site consisting of at least one cysteine. The invention relates to the use of the fusion proteins or of compositions comprising the fusion proteins for medical applications, such as diagnosis or treatment of cancer or cardiovascular diseases.
公开/授权文献
信息查询